Trexquant Investment LP Reduces Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Trexquant Investment LP cut its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 47.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 80,842 shares of the company’s stock after selling 74,350 shares during the quarter. Trexquant Investment LP’s holdings in Kiniksa Pharmaceuticals were worth $1,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP purchased a new position in Kiniksa Pharmaceuticals in the third quarter worth about $1,192,000. JPMorgan Chase & Co. purchased a new position in Kiniksa Pharmaceuticals in the third quarter worth about $4,997,000. SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals in the fourth quarter worth about $355,000. Charles Schwab Investment Management Inc. boosted its position in Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock worth $2,414,000 after purchasing an additional 32,393 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Kiniksa Pharmaceuticals in the fourth quarter worth about $3,955,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Stock Up 2.2 %

NASDAQ KNSA opened at $19.90 on Thursday. The stock’s 50-day moving average price is $20.96 and its 200-day moving average price is $21.69. The company has a market capitalization of $1.45 billion, a P/E ratio of -142.13 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period last year, the business posted $0.35 EPS. Research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on KNSA. Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $37.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. The trade was a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the sale, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock worth $2,011,735 in the last quarter. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.